A phase I study of peginterferon alfa-2b (PEG-INTRON) with sorafenib (Nexavar) in patients with unresectable or metastatic clear cell renal carcinoma (RCC).
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2015
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Sorafenib
- Indications Renal cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 22 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 May 2013 Lead trial center changed as reported by ClinicalTrials.gov.